IPO - CARLSMED, INC.

Form Type: S-1

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000095012325006117

Filing Summary: Carlsmed, Inc. is conducting an initial public offering (IPO) of its common stock through registration statement S-1 filed with the SEC. The company specializes in AI-enabled personalized spine surgery, aiming to improve outcomes and reduce healthcare costs associated with spine procedures. The offering is contingent upon obtaining approval to list shares on the Nasdaq under the symbol 'CARL.' Prior to this offering, there has been no public market for the shares. Carlsmed's technology, the aprevo Technology Platform, integrates AI to design custom interbody implants and develop comprehensive surgical plans tailored to individual patients, specifically targeting degenerative disc disease (DDD) and adult spinal deformity (ASD). The company holds 510(k) clearance from the FDA for its devices, which are also covered by various Medicare and commercial payers. The estimated total addressable market for the platform is approximately $13.4 billion in the U.S. alone, with significant anticipated growth due to increased provider adoption. As of March 31, 2025, Carlsmed reported impressive revenue growth and a strategic path towards expanding into cervical fusion technologies expected by 2026. The document discusses various risks associated with the investment, the company's clinical evidence supporting their platform, and their sales strategies, including direct sales and partnerships with independent agents.

Form Type: DRS/A

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000095012325005939

Filing Summary: Carlsmed, Inc. is undertaking an initial public offering (IPO) of its common stock. This DRS/A document is an amendment to a draft registration statement that remains confidential. The company specializes in AI-enabled personalized spine surgery solutions, aiming to establish a new standard of care for spine fusion surgery with its aprevo Technology Platform. This platform includes software solutions and custom-designed interbody implants tailored to individual patients. The IPO is contingent upon SEC approval, and it highlights the anticipated sale of shares, noting that prior to this offering, there has been no public market for its shares. The company expects to list on The Nasdaq Global Select Market under the symbol 'CARL'. The document also discusses potential market growth, existing shareholders' influence, and the risks associated with investing, including the potential for high revision rates after traditional spine surgery. The initial public offering aims to capitalize on an estimated annual addressable market of approximately $13.4 billion for their technology. The offering price details are not finalized, and the company is seeking to enhance its market presence through expanded sales and clinical validation efforts.

Form Type: DRS

Filing Date: 2025-04-24

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003656

Filing Summary: Carlsmed, Inc. is filing a preliminary prospectus for an initial public offering (IPO) of shares of common stock under the registration statement Form S-1 with the SEC. The offering represents Carlsmed's focus on pioneering AI-enabled personalized spine surgery solutions, aimed at improving healthcare outcomes and reducing costs associated with spine surgeries. The company plans to list its common stock on The Nasdaq Market under the symbol 'CARL' and anticipates an initial public offering price within an unspecified range. Currently, there is no public market for Carlsmed's shares. This document provides key details about the company’s operations, financial condition, and the potential market for their innovative products. With projections of substantial market size and potential revenue growth, the company emphasizes its technology as a solution to the limitations of traditional spine fusion surgeries, which often lead to high revision rates and significant economic burdens. The preliminary prospectus outlines various financial metrics, risks, and business strategies as Carlsmed prepares for its IPO.